M. James Barrett, Ph.D., Chairman of the Board of Directors
Dr. Barrett is currently a General Partner with the venture capital firm New Enterprise Associates, GlycoMimetics, Inc.'s lead investor. He founded Sensors for Medicine and Science, Inc. in 1997, and serves as Chairman of its board. In 1987, he founded Genetic Therapy, Inc. (GTI) which was sold in August of 1995 to Swiss pharmaceutical giant Sandoz AG (now Novartis) for $300-million. He continued to serve as GTI's CEO and as a Director through June 1996. From 1982 to July of 1987, Dr. Barrett served as President of Life Technologies, Inc. (now part of Invitrogen) and its predecessor, Bethesda Research Laboratories. Prior to 1982, he was employed at SmithKline Beecham Corporation for 13 years, where he held a variety of positions, including President of its In Vitro Diagnostics Division and President of SmithKline Clinical Laboratories. Dr. Barrett was a Director of MedImmune, Inc. from 1988 until its acquisition by AstraZeneca in 2007.

Michael Henos, Director
Mr. Henos is founder and managing general partner of Alliance Technology Ventures, a lead investor in GlycoMimetics, Inc. Prior to ATV, he was a general partner with Aspen Venture Partners where he was based in Menlo Park, CA. Prior to Aspen he was vice president of 3i Ventures in Newport Beach, CA. From 1984 to 1986 he was a health care consultant with Ernst & Young, specializing in venture financing of start-up medical technology companies. Prior to 1984 he served in a variety of management positions with Science Applications, Inc., the Revlon Healthcare Group and co-founded Pro Med Technologies, where he also served as its Chief Executive Officer.

William Gust, Director
Mr. Gust is General Managing Partner for Anthem Capital Management. He has 40 years of business experience with a strong emphasis on venture capital investing and the development of small rapidly growing businesses. During the past 25 years, he has invested successfully in a broad range of start-up and early stage companies all over the United States, including such companies as Apple Computer, Samna (Lotus Corporation’s word processor), HealthSouth and Chuck E. Cheese.

John J. Baldwin, Ph.D., Director
Dr. Baldwin co-founded Vitae Pharamaceuticals, Inc. in May 2001 and currently serves as the company's President and Chief Scientific Officer. Prior to that, he spent nine years at Pharmacopeia, Inc., where he was a co-founder and served as Chief Scientific and Technology Officer. Prior to Pharmacopeia, Dr. Baldwin was a Distinguished Senior Scientist at Merck & Co., where he spent 33 years in various scientific and management positions.

Franklin H. Top, Jr., M.D., Director
Dr. Top is Senior Vice President of MedImmune, Inc.'s biotechnology venture capital affiliate, MedImmune Ventures, Inc. Dr. Top joined MedImmune in June 1988 as Executive Vice President and was a member of its Board of Directors from 1988 through 2004. He became MedImmune's Medical Director in 1990, and most recently served as acting head of Medical Affairs. From 1987 to 1988, Dr. Top served as Senior Vice President for Clinical and Regulatory Affairs at Praxis Biologics. Prior to 1987, Dr. Top served for 22 years in the U.S. Army Medical Research and Development Command, where he was appointed Director, Walter Reed Army Institute of Research in 1983.